SPONSORED CONTENT

Translumina to set up Asia's Largest Heart Valve manufacturing facility at AMTZ Vizag

December 28, 2021 23:30 IST | ANI Press Release
Tennis player James Blake
Translumina to set up Asia's largest Heart Valve manufacturing facility at AMTZ Vizag

New Delhi [India]/ Hechingen [Germany], December 28 (ANI/PRNewswire): Translumina, a global developer and manufacturer of innovative cardiovascular medical devices used in interventional cardiology, performed the foundation stone laying ceremony of Asia's Largest Heart Valve manufacturing facility at Andhra Pradesh Medtech Zone (AMTZ) in Vizag.

"It is a moment of great pride for all of us to enter the market of Transcatheter valves. We have partnered with some of the best institutions and physicians around the world to create next-generation heart valve technologies to offer better clinical outcomes at an affordable cost for all kinds of valve disorders." said Gurmit Singh Chugh, MD and Co-founder, Translumina.

Heart valve disorders which traditionally were treated by an open-heart Surgery, are prevalent significantly worldwide. However, in the last few years, Transcatheter Heart valve Implantation (using a catheter without opening the heart) has made the procedure simple, safe and effective with a minimally invasive approach. However, the prohibitive cost of the transcatheter valves, along with niche indications, have made therapy limited to very few patients.

"We plan to complete the facility by December 2022 with more than 100,000 square feet of manufacturing space with the state-of-the-art equipment and infrastructure," said Punita Sharma Arora, Co-Founder, Translumina.

Translumina has an excellent track record of creating path-breaking technologies bundled with high quality and robust clinical data. In 2020, Translumina became the only company in the world to publish 10-year follow-up data on two DES technologies. Last year, the Journal of the American College of Cardiology (JACC) published 10-year follow-up data on Translumina's dual-drug polymer-free Drug Eluting stent (DES) VIVO ISAR. In 2018, Translumina became the first company in the world to present 10-year follow-up data on Yukon in a head-to-head study against Xience (Abbott Inc. USA). The study, called ISAR-TEST 4 trial, was presented at the 2018 American Heart Association meeting, and was simultaneously published in Circulation.

"We are pleased to welcome Translumina to AMTZ Family for developing Asia's largest Valve manufacturing facility. Translumina over the years, has created various cutting-edge technologies of very high quality for global markets and I am sure that this endeavour will also disrupt the market of Transcatheter Valves by combining innovation, quality and affordability," said Dr Jitendra Sharma, CEO, Andhra Pradesh Medtech Zone (AMTZ), Vizag.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

 

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Translumina to set up Asia's Largest Heart Valve manufacturing facility at AMTZ Vizag

New Delhi [India]/ Hechingen [Germany], December 28 (ANI/PRNewswire): Translumina, a global developer and manufacturer of innovative cardiovascular medical devices used in interventional cardiology, performed the foundation stone laying ceremony of Asia's Largest Heart Valve manufacturing facility at Andhra Pradesh Medtech Zone (AMTZ) in Vizag.

"It is a moment of great pride for all of us to enter the market of Transcatheter valves. We have partnered with some of the best institutions and physicians around the world to create next-generation heart valve technologies to offer better clinical outcomes at an affordable cost for all kinds of valve disorders." said Gurmit Singh Chugh, MD and Co-founder, Translumina.

Heart valve disorders which traditionally were treated by an open-heart Surgery, are prevalent significantly worldwide. However, in the last few years, Transcatheter Heart valve Implantation (using a catheter without opening the heart) has made the procedure simple, safe and effective with a minimally invasive approach. However, the prohibitive cost of the transcatheter valves, along with niche indications, have made therapy limited to very few patients.

"We plan to complete the facility by December 2022 with more than 100,000 square feet of manufacturing space with the state-of-the-art equipment and infrastructure," said Punita Sharma Arora, Co-Founder, Translumina.

Translumina has an excellent track record of creating path-breaking technologies bundled with high quality and robust clinical data. In 2020, Translumina became the only company in the world to publish 10-year follow-up data on two DES technologies. Last year, the Journal of the American College of Cardiology (JACC) published 10-year follow-up data on Translumina's dual-drug polymer-free Drug Eluting stent (DES) VIVO ISAR. In 2018, Translumina became the first company in the world to present 10-year follow-up data on Yukon in a head-to-head study against Xience (Abbott Inc. USA). The study, called ISAR-TEST 4 trial, was presented at the 2018 American Heart Association meeting, and was simultaneously published in Circulation.

"We are pleased to welcome Translumina to AMTZ Family for developing Asia's largest Valve manufacturing facility. Translumina over the years, has created various cutting-edge technologies of very high quality for global markets and I am sure that this endeavour will also disrupt the market of Transcatheter Valves by combining innovation, quality and affordability," said Dr Jitendra Sharma, CEO, Andhra Pradesh Medtech Zone (AMTZ), Vizag.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22